The endogenous cannabinoid system and its role in nociceptive behavior

Journal of Neurobiology

Volumn 61, Issue 1, 2004, Pages 149-160

  Cravatt, Benjamin F ^a   Lichtman, Aron H ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Agonist; Antagonist; Cannabinoid; CB1 receptor; CB2 receptor; Endocannabinoid; Fatty acid amide hydrolase; Inhibitor; Pain

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; ETHANOLAMINE; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; MONOACYLGLYCEROL; TETRAHYDROCANNABINOL;

DRUG EFFECT; ENZYME DEGRADATION; GENE DISRUPTION; IMMUNE SYSTEM; IMMUNOMODULATION; MOLECULAR MECHANICS; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; STIMULUS RESPONSE; SYNTHESIS;

ANIMALS; ENDOCANNABINOIDS; HUMANS; PAIN; PAIN MEASUREMENT; RECEPTORS, CANNABINOID;

EID: 4644372326     PISSN: 00223034     EISSN: None     Source Type: Journal    
DOI: 10.1002/neu.20080     Document Type: Review

References (109)

1. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. 2000. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 100:685-688.
2. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Guhring H. 2003. Intrathecally applied fluribiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur J Neurosci 17:597-604.
3. Basile AS, Hanus L, Mendelson WB. 1999. Characterization of the hypnotic properties of oleamide. Neuroreport 10:947-951.
4. Beaulieul P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice AS. 2000. Role of endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396:85-92.
5. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. 1997. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097.
6. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, et al. 2003. Cloning of the first sn1-DAG upases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463-468.
7. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF. 2000. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 97:5044-5049.
8. Bridges D, Ahmand K, Rice AS. 2001. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133:586-594.
9. Cadas H, di Tomaso E, Piomelli D. 1997. Occurence and biosynthesis of endogenous cannabinoid precursor, N-arachidonyl phosphatidylethanolamine, in rat brain. J Neurosci 17:1226-1242.
10. Calignano A, La Rana G, Giuffrida A, Piomelli D. 1998. Control of pain initiation by endogenous cannabinoids. Nature 394:277-281.
11. Chapman V. 1999. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br J Pharmacol 127:1765-1767.
12. Chapman V. 2001. Functional changes in the inhibitory effect of spinal cannabinoid receptor activation in nerve injured rats. Neuropharmacology 41:870-877.
13. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. 2002. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96:253-260.
14. Clement AC, Hawkins EG, Lichtman AH, Cravatt BF. 2003. Increased seizure susceptibility and pro-convulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci 23:3916-3923.
15. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. 2002. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135:181-187.
16. Costa B, Colleoni M. 1999. SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Zhongguo Yao Li Xue Bao 20:1103-1108.
17. Costa B, Colleoni M, Conti S, Trovato AE, Bianchi M, Sotgui ML, Giagnoni G. 2004. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 141:4-8.
18. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. 2001. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376.
19. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
20. Cravatt BF, Lichtman AH. 2002. The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 121:135-148.
21. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA. 1995. Chemical characterization of a family of brain lipids that induce sleep. Science 268:1506-1509.
22. Devane WA, Hanus L, Breur A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
23. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Martin BR. 1999. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr Med Chem 6:721-744.
24. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. 2002. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66:377-391.
25. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, et al. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825.
26. Dinh TP, Freund TF, Piomelli D. 2002. A role for monoacylglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002:149-158.
27. Dogrul A, Gardell LR, Ma S, Ossipov MH, Porreca F, Lai J. 2002. "Knock-down" of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice. Pain 100:203-209.
28. Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V. 2000. Activation of spinal cannabinoid I receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35]SGTPgammaS bindiing in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 12:2079-2086.
29. Egertova M, Giang DK, Cravatt BF, Elphick MR. 1998. A new perspective on cannabinoid signalling: Complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B 265:2081-2085.
30. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR. 2000. Cannabinoid CB1 receptor expression in rat spinal cord. Mol Cell Neurosci 15:510-521.
31. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I. 2001. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92:91-100.
32. Fukushima N, Ishii I, Contos JJ, Weiner JA, Chun J. 2001. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 41:507-534.
33. Giuffrida A, Beltramo M, Piomelli D. 2001. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 298:7-14.
34. Glaser ST, Abumrad N, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. 2003. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100:4269-4274.
35. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. 1998. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEES Lett 422:69-73.
36. Goya P, Jagerovic N, Hernandez-Folgado L, Martin MI. 2003. Cannabinoids and neuropathic pain. Mini Rev Med Chem 3:765-772.
37. Hanus L, Breur A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E. 1999. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96:14228-14233.
38. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. 1997. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuorpathic pain. Neurosci Lett 221:157-160.
39. Hillard CJ, Jarrahian A. 2000. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 108:123-134.
40. Hohmann AG. 2002. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological, and neuroanatomical perspectives. Chem Phys Lipids 31:173-190.
41. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. 2004. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308:446-453.
42. Hohmann AG, Martin WJ, Tsou K, Walker JM. 1995. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci 56:2111-2118.
43. Hohmann AG, Tsou K, Walker JM. 1998. Cannabinoid modulaton of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55.212-2. Neurosci Lett 257:119-122.
44. Ibrahim MM, Deng H, Zvonok AM, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, et al. 2003. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100:10529-10533.
45. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T. 2001. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for the cannabinoid CB2 receptor. J Pharmacol Exp Ther 296:420-425.
46. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. 1998. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76:189-199.
47. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
48. Kelly S, Chapman V. 2001. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophys 86:3061-3064.
49. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. 1997. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 331:R1-R2.
50. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, et al. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
51. Leung D, Hardouin C, Boger DL, Cravatt BF. 2003. Discovering potent and selective inhibitors of enzymes in complex proteomes. Nat Biotechnol 21:687-691.
52. Lichtman AH, Cook SA, Martin BR. 1996. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276:585-593.
53. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF. 2002. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302:73-79.
54. Lichtman AH, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger DL, Cravatt BF. 2004a. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther, to appear.
55. Lichtman AH, Martin BR. 1991. Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J Pharmacol Exp Ther 258:517-523.
56. Lichtman AH, Martin BR. 1997. The selective cannabinoid antagonist, SR141716A, blocks cannabinoid-induced antinociception following intraventricular administration in rats. Brain Res 629:300-304.
57. Lichtman AH, Shelton CC, Advani T, Cravatt BF. 2004b. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109:319-327.
58. Lichtman AH, Smith PB, Martin BR. 1992. The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity. Pain 51:19-26.
59. Lim G, Sung B, Ji RR, Mao J. 2003. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behavior in rats. Pain 105:275-283.
60. Maccarrone M, Bari M, Battista N, Finazzi-Agro A. 2002. Endocannabinoid degradation, endotoxic shock, and inflammation. Curr Drug Targets Inflamm Allergy 1:53-63.
61. Malan TP, Ibrahim MM, Deng H, Liu H, Mata HP, Vanderah TW, Porreca F, Makriyannis A. 2001. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93:239-245.
62. Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A. Porreca F. 2002. Inhibition of pain responses by activation to CB2 cannabinoid receptors. Chem Phys Lipids 121:191-200.
63. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B. 2002. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534.
64. Martin BR, Lichtman AH. 1998. Cannabinoid transmission and pain perception. Neurobiol Dis 5:447-461.
65. Martin WJ, Hohmann AG, Walker JM. 1996. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptiv effects. J Neurosci 16:6601-6611.
66. Martin WJ, Lai NK, Patrick SL, Tsou K, Walker JM. 1993. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res 629:300-304.
67. Martin WJ, Loo CM, Basbaum AI. 1999. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 82:199-205.
68. Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. 1995. An examination of central sites of action of cannabinoid-induced antinociception in the rat. Life Sci 56:2103-2109.
69. Massa F, Marsicano G, Hermann H, Cannich A, Memory K, Cravatt BF, Ferri G-L, Sibaev A, Storr M, Lutz B. 2004. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202-1209.
70. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
71. Mechoulam R. 1986. The pharmacohistory of Cannabis sativa. Boca Raton, FL: CRS Press.
72. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds cannabinoid receptors. Biochem Pharmacol 50:83-90.
73. Mechoulam R, Fride E, Hanus L, Sheskin T, Bisogno T, Di Marzo V, Bayewitch M, Vogel Z. 1997. Anandamide may mediate sleep induction. Nature 389:25-26.
74. Meng ID, Manning BH, Martin WJ, Fields HL. 1998. An analgesia circuit activated by cannabinoids. Nature 395:381-383.
75. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, et al. M. 1999. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 80:67-82.
76. Monhemius R, Azami J, Green DL, Roberts MH. 2001. CB1 receptor mediated analgesia from the nucleus reticularis gigantocellularis pars alpha is activated in an anmial model of neuropathic pain. Brain Res 908:67-74.
77. Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
78. Nackley AG, Makriyannis A, Hohmann AG. 2003. Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119:747-757.
79. Nilius B, Vriens J, Prenen J, Droogmans G, Voets T. 2004. TRPV4 calcium entry channel: a paradigm for gating diversity. Am J Physiol Cell Physiol 286:C195-205.
80. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. 2004. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298-5305.
81. Patricelli, MP, Cravatt, BF. 2001. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vitam Horm 62:95-131.
82. Pertwee RG. 2001. Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
83. Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B, Barth F, le Fur G, Casellas P. 1999. SR 1444528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther 288:582-589.
84. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP. 2003. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99:955-960.
85. Rice AS. 2001. Cannabinoids and pain. Curr Opin Investig Drugs 2:399-414.
86. Richardson JD, Aanonsen L, Hargreaves K. 1998a. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 18:451-457.
87. Richardson JD, Kilo S, Hargreaves KM. 1998b. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119.
88. Rinaldi-Carmona M, et al. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEES Lett 350:240-244.
89. Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, Murillo-Rodriguez E, Giuffrida A, LoVerme J, Gaetani S, et al. 2001. An anorexic lipid mediator reguated by feeding. Nature 414:209-212.
90. Sanudo-Pena MC, Strangman NM, Mackie K, Walker JM, Tsou K. 1999. CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Zhongguo Yao Li Xue Bao 20:1115-1120.
91. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, Ferrara P. 1999. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 65:627-635.
92. Siegling A, Hofmann HA, Denzer D, Mauler F, Vry D. 2001. Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415:R5-R7.
93. Sit S-Y, Xie K. 2002. Bisarylimidazolyl fatty acid amide hydrolase inhibitors. Patent W0 02/087569.
94. Sit S-Y, Xie K. 2003. (Oxime)carbamoyl fatty acid amide hydrolase inhibitors. Patent Application US 2003/0195226 A1.
95. Smith FL, Fujimori K, Lowe J, Welch SP. 1998. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 60:183-191.
96. Smith PB, Martin BR. 1992. Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J Pharmacol Exp Ther 258:517-523.
97. Stella N, Schweitzer P, Piomelli D. 1997. A second endogenous cannabinoid that modulates long term potentiation. Nature 388:773-778.
98. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. 1998. Evidence for a role for endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res 813:323-328.
99. Strangman NM, Walker JM. 1999. The cannabinoid WIN 55,212-2 inhibits the activity dependent facilitation of spinal nociceptive responses. J Neurophys 81:472-477.
100. Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, Yamshita A, Waku K. 1996. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonylethanolamine, an endogenous cannabinoid receptor ligand in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur J Biochem 240:53-62.
101. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM, 1998. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
102. Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP, 2000. Reduction of stress-induced analgesia but not exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 12:533-539.
103. Varvel SA, Lichtman AH. 2002. Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301:915-924.
104. Walker JM, Huang SM. 2002. Cannabinoid analgesia. Pharmacol Ther 95:127-135.
105. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. 1999. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96:12198-12203.
106. Yaksh TL. 1981. The antinociceptive effects of intrathecally-administered levonantradol and deacetyllevonantradol in the rat. J Clin Pharmacol 21:3348-3408.
107. Zhang J, Hoffet C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. 2003. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17:2750-2754.
108. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. 1999. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci 96:5780-5785.
109. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. 1999. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457.